Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VXB-213 is a monovalent protein subunit vaccine candidate developed by Vicebio for the prevention of respiratory syncytial virus (RSV) infection. The vaccine utilizes proprietary Molecular Clamp technology, which is designed to lock viral fusion proteins into their native, pre-fusion trimeric conformation. This stabilization is critical for exposing key epitopes that elicit high titers of neutralizing antibodies. VXB-213 is being evaluated in clinical trials both as a standalone monovalent vaccine and as a comparator component for multivalent candidates, including the bivalent VXB-241 (RSV/hMPV) and the trivalent VXB-251 (RSV/hMPV/PIV3). It is administered via intramuscular injection and is primarily targeted at older adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VXB-213.